Tomaž Bratkovič,Abida Zahirović,Maruša Bizjak,Maja Rupnik,Borut Štrukelj,Aleš Berlec
Abstract:Clostridioides difficile causes a range of debilitating intestinal symptoms that may be fatal. It is particularly problematic as a hospital-acquired infection, causing significant costs to the health care system. Antibiotics, such as vancomycin and fidaxomicin, are still the drugs of choice for C. difficile infections, but their effectiveness is limited, and microbial interventions are emerging as a new treatment option. This paper focuses on alternative treatment approaches, which are currently in various stages of development and can be divided into four therapeutic strategies. Direct killing of C. difficile (i) includes beside established antibiotics, less studied bacteriophages, and their derivatives, such as endolysins and tailocins. Restoration of microbiota composition and function (ii) is achieved with fecal microbiota transplantation, which has recently been approved, with standardized defined microbial mixtures, and with probiotics, which have been administered with moderate success. Prevention of deleterious effects of antibiotics on microbiota is achieved with agents for the neutralization of antibiotics that act in the gut and are nearing regulatory approval. Neutralization of C. difficile toxins (iii) which are crucial virulence factors is achieved with antibodies/antibody fragments or alternative binding proteins. Of these, the monoclonal antibody bezlotoxumab is already in clinical use. Immunomodulation (iv) can help eliminate or prevent C. difficile infection by interfering with cytokine signaling. Small-molecule agents without bacteriolytic activity are usually selected by drug repurposing and can act via a variety of mechanisms. The multiple treatment options described in this article provide optimism for the future treatment of C. difficile infection.
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve
This paper aims to explore and evaluate new treatment strategies for **Clostridioides difficile infections (CDI)**, particularly those that can serve as alternatives to antibiotics and fecal microbiota transplantation (FMT). Specifically, the paper focuses on the following four main treatment strategies:
1. **Directly Killing Clostridioides difficile**:
- This includes known antibiotics, bacteriophages, and their derivatives (such as lysins and tailocins).
2. **Restoring the Composition and Function of the Gut Microbiome**:
- Achieved through fecal microbiota transplantation (FMT), standardized microbial mixtures, and probiotics. FMT has been approved for treating recurrent CDI but has some logistical, safety, and acceptance issues. Therefore, researchers are exploring other alternatives, such as complex microbiome-based live biotherapeutic products.
3. **Neutralizing Clostridioides difficile Toxins**:
- The exotoxins produced by Clostridioides difficile (such as toxin A and toxin B) are key factors in its pathogenicity. Neutralizing these toxins can be achieved through antibodies or antibody fragments and alternative binding proteins. Currently, the monoclonal antibody bezlotoxumab is already in clinical use.
4. **Immune Modulation**:
- Helping to eliminate or prevent Clostridioides difficile infection by interfering with cytokine signaling. These small molecule drugs are often selected through drug repurposing and can act through various mechanisms.
### Background
Clostridioides difficile is a Gram-positive, strictly anaerobic, spore-forming bacterium that is widely present in the environment, primarily inhabiting the intestines of humans and various animals. Infection begins with the ingestion of spores, which germinate in the small intestine and proliferate in the colon. Dysbiosis of the gut microbiota favors the colonization of Clostridioides difficile. Clostridioides difficile can cause a range of pathological symptoms, from mild self-limiting diarrhea to severe diarrhea, pseudomembranous colitis, and even life-threatening fulminant colitis. About 20% of patients experience recurrence after the initial infection, which is one of the most significant clinical issues. Each year in the United States and Europe, Clostridioides difficile infections result in approximately 780,000 cases and 49,000 deaths, with the cost of treating and managing CDI being very high.
### Current Treatment Status
Currently, the most commonly used treatments for CDI are still antibiotics, such as vancomycin and fidaxomicin. However, Clostridioides difficile spores can survive antimicrobial treatment, leading to CDI recurrence. In recent years, microbial management has become the second most important treatment option, aiming to restore the composition and function of the microbiome.
Despite the significant success of antibiotics and microbial interventions, new approaches are still needed. This paper particularly focuses on these alternative or supplementary strategies, which are either newly entering the field or already well-established. The paper outlines the treatment strategies for CDI through simplified schematic diagrams.